Loading...
Glatiramer acetate treatment negatively regulates type I interferon signaling
OBJECTIVE: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-...
Na minha lista:
Udgivet i: | Neurol Neuroimmunol Neuroinflamm |
---|---|
Main Authors: | , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Lippincott Williams & Wilkins
2015
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4645172/ https://ncbi.nlm.nih.gov/pubmed/26601118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000179 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|